Abstract: Compositions, methods, and systems for modifying sterol metabolism in a subject is disclosed. In some embodiments, the subjects may be administered one or more mammalian cells modified to express at least one sterol degrading enzyme derived from a bacterium. In many embodiments, the cell is a macrophage or monocyte stably expressing three or more enzymes that aid in opening the ? ring of cholesterol. The disclosed compositions and methods may be useful in lowering cholesterol levels in a subject in need thereof. In some embodiments, the subject may have a genetic predisposition to atherosclerosis.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/?l. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

Abstract: A method for enhancing male sexual wellness with shockwave therapy and stem cells promotes tissue repair and regeneration in or near the male penis, through the combinative effects of shockwave therapy and needle-free injection of a stem cell specimen on the penile surface of the penis. The method includes: preparing the male patient, both mentally and physically to receive stem cell therapy; applying shockwave therapy to the penis; developing a platelet-rich plasma preparation from the patient; introducing a stem cell specimen into a vial having a needle-free injector; introducing the platelet-rich plasma preparation into the vial; injecting, through the needle-free injector, the stem cell specimen and platelet-rich plasma preparation directly on penile surface from multiple positions, multiple depths, and multiple angles; reapplying shockwave therapy to the penis after a duration; and monitoring the patient for a post-procedure duration after administration of the stem cell specimen to the penis.

Abstract: Preparations comprising microorganisms for delivery as a plurality of particles, kits including microorganism preparations for delivery as a plurality of particles, and devices for administering microorganism preparations as a plurality of particles are provided. Methods of administering microorganisms via nebulization or inhalation are provided. Methods of introducing microorganisms to the respiratory system are provided. Methods of treating disorders, including respiratory disorders and inflammatory disorders, with preparations comprising microorganisms are provided.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome.

Abstract: A method of treating a headache, e.g., a migraine, in a subject is provided. The method comprises administering a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the headache. Related preparations, kits, and devices are also provided.

Abstract: The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions.

Abstract: Provided is a pharmaceutical composition and food composition for treating or preventing a skin disease caused by abnormal growth of a skin bacterium or infection with a pathogenic microorganism. A composition comprising a lactic acid bacterium as an active ingredient, for suppressing bacterial abnormal growth, or preventing or ameliorating deterioration of skin condition caused by a bacterial abnormal growth, by oral intake thereof.

Abstract: The present invention is directed to an aerosol spray containing one or more bacterial species and at least one siloxane suitable for applying said one or more bacterial species to a surface or into the environment.

Abstract: The invention relates to the use of a bacterial mixture for the prevention and improvement of the state of ungulates suffering from pathologies involving a parasitic or bacterial infection of the foot, said composition comprising: at least one strain of bacteria of the genus Bacillus, and at least one lactic acid bacterium.

Abstract: Based on the microbiological and biochemical characteristics of a novel strain of lactic acid bacteria emerged in the fermentation process of a vegetable and brown sugar fermentation beverage, a better immunostimulant and a health care food, a pharmaceutical composition and the like including the immunostimulant are provided. Disclosed are an isolated bacterial strain of Lactobacillus kosoi 10H deposited under the accession number NITE BP-02811, and a composition comprising the isolated bacterial strain or a culture product thereof.

Abstract: Methods and materials for intrathecal delivery of recombinant Adeno-associated virus 9 (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) are provided. Use of the methods and materials is contemplated, for example, for the treatment of Rett syndrome.

Abstract: An agent is described that includes a plant virus particle or VLP conjugate to TRAIL. Associating TRAIL with the plant virus particle or VLP serves to both target cancer cells and induce their apoptosis. The agent can therefore be used for a method of treating cancer in a subject.

Abstract: The present invention relates to Saccharomyces boulardii yeast cells, for use in the prevention or treatment of mood disorders, in a person.

Abstract: Embodiments of the invention include a system having a plant stem cell product and a delivery device configured to deliver an effective amount of the plant stem cell product to the oral cavity or nasopharynx. In some embodiments, the delivery device may include an aerosolizing device, an adherent dressing, a tooth-adherent flexible strip, a treatment tray, a viscous adherent carrier, a brush, a paste, a flosser, a dissolving oral strip, a gum, a chew, a smoking material, a nasal packing, or a lozenge. The plant stem cell products may include encapsulated extracts of plant stem cells, such as food species stem cells, spice or other seasoning stem cells, or medicinal plant stem cells.

Abstract: Various aspects of this patent application relate to methods to separate a cannabinoid molecule from other molecules of a decarboxylated cannabinoid extract.

Abstract: A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family (Flavivirus genus), Deltaretrovirus genus, or Togaviriade family is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can futher include at least one triterpene. Alternatively, the composition comprises at least one, at leat two, or at least three triterpenes.

Abstract: Antimicrobial, antiviral and antifungal composition and methods of use thereof are provided.

Abstract: The invention provides a composition and method for treating dyspepsia with asafoetida and milk thistle extract. A method of making the inventive composition is contemplated.

Abstract: A method of reducing the appearance of fine lines or wrinkles or increasing skin elasticity or skin firmness is disclosed. The method can include topically applying to the fine line or wrinkle or to sagging or loose skin an effective amount of a topical composition comprising a combination of vegetable amino acids from navy bean, Myrciaria dubia fruit extract, Peucedanum graveolens extract, and tetrahexyldecyl ascorbate. The combination can reduce the appearance of the fine line or wrinkle, increases skin elasticity, or increases skin firmness.

Abstract: Provided is a method of preparing an orange peel ferment, an orange peel ferment obtained therefrom, and a method for reducing fat accumulation, sleep disturbance, and cancer risk. The orange peel ferment assists obese individuals to slim down via multiple mechanisms including reducing the fat content of adipocytes, promoting lysis of triglycerides in adipocytes, and enhancing the expression of genes involved in fat metabolism, and also reduces sleep disturbance through normalizing circadian rhythm and lowers cancer risk through suppressing expression of cancer risk genes.

Abstract: The invention provides a composition rich in flavonoids based on natural extracts, comprising a flavonoid extract dispersed by melt mixing or extrusion and encapsulated in a polymer matrix. The invention is also a novel dietary supplement with the naturally occurring ingredient (?)-epicatechin, cacao extracted, that could potentially prevent or reduce the risk of Atherosclerotic pathology. The use of (?)-epicatechin is promising as a therapeutic agent due to its potential antioxidant activity and its diverse biological properties. (?)-Epicatechins are chemically unstable and extensively degraded in fluids of near neutral or greater pH, such as intestinal juice and bile. Current technologies used for taste masking and modified release as spray drying, liposome entrapment, co-crystallization, freeze drying, among others, suffer from numerous shortcomings, including poor repeatability and limitations on target delivery.

Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.

Abstract: Disclosed herein are methods for treating or preventing a hypoperfusion related disease in a subject in need thereof, comprising identifying a subject with cerebral hypoperfusion and administering an effective amount of an ?5?1 integrin inhibitor to the subject. Methods for decreasing ?5?1 expression in the cerebrovasculature, comprising: administering an effective amount of an ?5?1 integrin inhibitor to a subject in need thereof are also disclosed. A method for preventing or decreasing the risk of developing diabetes related dementia, comprising: identifying a subject with diabetes and administering an effective amount of an ?5?1 integrin inhibitor to the subject is further disclosed.

Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).

Abstract: Disclosed is a pharmaceutical composition or food composition for the treatment or prevention of hypertension, containing a peptide isolated from a fraction of a flounder surimi hydrolysate as an active ingredient and is based on the finding that the flounder surimi has an effect of reducing blood pressure, and the hydrolysate of the flounder surimi, the fraction of the hydrolysate of the flounder surimi and peptides isolated from the fraction of the hydrolysate of the flounder surimi have an inhibition activity against an angiotensin I converting enzyme (ACE). Thus, peptides isolated from the fraction of the hydrolysate of the flounder surimi can be used for pharmaceutical compositions or food compositions for treating or preventing hypertension.

Abstract: Compositions for and methods of treating corneal injury, among other tissue of or around the eye, are provided. Said compositions comprise MG53 or express MG53. Said compositions can be used for treating chronic or acute injured tissue of the eye or orbit of the eye and can be administered systemically, locally, or both.

Abstract: Methods and FSP27 compositions for treating and/or preventing metabolic disease and conditions associated insulin resistance, obesity, inflammation and dyslipidemia are described.

Abstract: The present invention provides a method for the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery, comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for use in the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery.

Abstract: The use of a composition for preventing or reducing the risk of inflammation of the bowel in an animal, wherein the composition contains beta-casein and wherein the beta-casein comprises at least 50% by weight beta-casein A2.

Abstract: The invention provides methods for treating pediatric inflammatory bowel disease patients using vedolizumab.

Abstract: The invention relates to an ELABELA polypeptide or nucleic acid for use in the treatment, alleviation or prophylaxis of pre-eclampsia in an individual. In another aspect of the invention, there is provided a method of diagnosing or detecting the susceptibility of an individual to pre-eclampsia, wherein the method comprises detecting modulation, preferably down-regulation of expression, amount or activity of ELABELA.

Abstract: The present invention relates to a secretin receptor modulator for use in the prevention and/or treatment of a disease or disorder of energy homeostasis, wherein (a) said secretin receptor modulator is a secretin receptor agonist and said disease or disorder is obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia, high blood pressure or metabolic syndrome, whereby the secretin receptor agonist increases non-shivering thermogenesis in brown adipocytes and/or increases the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or decreases food intake in a UCP1-dependent manner resulting in the prevention and/or treatment of said disease or disorder; or (b) said secretin receptor modulator is a secretin receptor antagonist and said disease or disorder is cachexia.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, include at least: a) a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, b) m-cresol in a concentration lower than or equal to 30 mM, and c) a co-polyamino acid bearing carboxylate charges and at least one Formula X hydrophobic radical.

Abstract: The present invention provides a composition for delivering a polynucleotide into cells via a polyplex. The polyplex comprises the polynucleotide and a polymer. The composition comprises the polyplex, a collagen-mimetic peptide (CMP) and collagen fragments. The CMP is bound to the polyplex and the collagen fragments. Also provided are the uses of the composition in methods of delivering a polynucleotide into cells as well as methods of improving wound healing in a subject, enhancing cell proliferation in a subject, enhancing production of extracellular matrix by cells in a subject and/or enhancing cell migration by cells in a subject.

Abstract: The invention provides methods for activating a repressed allele within an imprinting control region, thereby treating an imprinting associated disorder.

Abstract: Provided are methods of treating metachromatic leukodystrophy comprising administering to a subject in need of treatment a therapeutically effective amount of recombinant arylsulfatase A enzyme.

Abstract: The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment.

Abstract: Described herein are methods and compositions for treating a glucose 6 phosphatase deficiency based on mRNA therapy.

Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.

Abstract: Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional analytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional analytes.

Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.

Abstract: This invention provides methods to treat or prevent cervical dystonia, a disorder related thereto, or a symptom thereof, with novel injectable compositions comprising botulinum toxin that may be administered to a subject suffering from such maledy. The injectable compositions and methods in which these compositions are used provide novel and advantageous treatments which result in high responder rates and long duration of effect, for example, a duration of effect for 24 weeks and longer.

Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a soluble allofactor and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore.

Abstract: Only limited success has been previously achieved from cancer vaccines targeting unmodified tumor-associated self-antigens and new compositions and methods are needed. Immunogenic compositions and methods of use thereof are provided according to the present disclosure which include a protein effective to stimulate immune activity against a tumor-associated self-antigen, or a variant thereof which is a tumor-associated self-antigen.

Abstract: The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.